Lexeo Therapeutics (LXEO) EBT (2022 - 2026)

Lexeo Therapeutics has disclosed EBT across 5 years of filings, most recently posting -$20.2 million for Q1 2026.

• EBT for Q1 2026 came in at -$20.2 million, up 38.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$87.5 million (up 19.95% YoY), and the FY2025 annual result was -$103.2 million, down 4.97% from the prior year.
• EBT came in at -$20.2 million for Q1 2026 at Lexeo Therapeutics, up from -$20.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$13.4 million in Q2 2023 to a low of -$32.7 million in Q1 2025.
• The 5-year median for EBT is -$20.3 million (2025), against an average of -$21.1 million.
• Across the five-year window, EBT sank 82.73% in 2024 and jumped 38.16% in 2026, its largest moves.
• Lexeo Therapeutics' EBT stood at -$14.6 million in 2022, then grew by 2.68% to -$14.2 million in 2023, then sank by 82.73% to -$25.9 million in 2024, then increased by 19.29% to -$20.9 million in 2025, then grew by 3.47% to -$20.2 million in 2026.
• The last three EBT figures came in at -$20.2 million (Q1 2026), -$20.9 million (Q4 2025), and -$20.3 million (Q3 2025), per Business Quant data.